In the last trading session, 1,063,557 shares of the CytomX Therapeutics, Inc. (NASDAQ:CTMX) were traded, and its beta was 0.62. Most recently the company’s share price was $8.19, and it changed around -$0.19 or -0.02% from the last close, which brings the market valuation of the company to $530.58 Million. CTMX currently trades at a discount to its 52-week high of $15.44, offering almost -88.52% off that amount. The share price’s 52-week low was $6.25, which indicates that the current value has risen by an impressive 23.69% since then. We note from CytomX Therapeutics, Inc.’s average daily trading volume that its 10-day average is 735.33 Million shares, with the 3-month average coming to 1.03 Million.
CytomX Therapeutics, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2.1. If we narrow it down even further, the data shows that none out of 11 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 3 recommended CTMX as a Hold, whereas 8 deemed it a Buy, and no one rated it as Underweight. CytomX Therapeutics, Inc. is expected to report earnings per share of -$0.35 for the current quarter.
CytomX Therapeutics, Inc. (NASDAQ:CTMX): Trading Information
Although CTMX has showed a red trend with a performance of -2.27% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $8.42- on Tuesday, Apr 06 increased the stock’s daily price by 2.73%. The company’s shares are currently up 0.25% year-to-date, but still up 0.0791 over the last five days. On the other hand, CytomX Therapeutics, Inc. (NASDAQ:CTMX) is 0.05% up in the 30-day period. We can see from the shorts that 3.92 Million shares have been sold at a short interest cover period of 3.81 day (s).
The consensus price target as assigned by Wall Street analysts is $13.28, which translates to bears needing to increase their stock price by 62.15% from its current value. Analyst projections state that CTMX is forecast to be at a low of $8.5 and a high of $18. In order for the stock price to hit the forecast high, the stock would need to surge +119.78% from its current level, while the stock would need to crash 3.79% from its current level to reach the projected low.
CytomX Therapeutics, Inc. (CTMX) projections and forecasts
CytomX Therapeutics, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +26.58 percent over the past six months and at a 74.65% annual growth rate that is well above the industry average of 8.2%. However, despite this, analysts have decided to cut back on their fiscal year 2021 revenue estimates. The rating firms predict that it will lose -234.6% in revenue this quarter, and will report a decline of -11.8% in the next quarter. The year-over-year growth rate is expected to be -33.8%, down from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of $15.43 Million in revenue for the current quarter. 10 analysts expect CytomX Therapeutics, Inc. to make $15.36 Million in revenue for the quarter ending June 01, 2021. The company’s sales for the same quarter a year ago was $19.88 Million. Analysts predict that the company’s current quarter sales will drop, forecast at -22.4%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 32%. CytomX Therapeutics, Inc. earnings are expected to increase by 68.4% in 2021, but the outlook is negative -0.9% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 2.06% of CytomX Therapeutics, Inc. shares, and 74.57% of them are in the hands of institutional investors. The stock currently has a share float of 76.14%. CytomX Therapeutics, Inc. stock is held by 193 institutions, with BVF Inc. being the largest institutional investor. By Dec 30, 2020, it held 8.61% of the shares, which is about 5.58 Million shares worth $36.53 Million.
Blackrock Inc., with 5.87% or 3.81 Million shares worth $24.92 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Victory Portfolios-Victory RS Small Cap Growth Fund were the top two Mutual Funds as of Dec 30, 2020. The former held 1227561 shares worth $8.04 Million, making up 1.89% of all outstanding shares. On the other hand, Victory Portfolios-Victory RS Small Cap Growth Fund held roughly 1.2 Million shares worth around $7.85 Million, which represents about 1.85% of the total shares outstanding.